The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Nurix Therapeutics Reports Wider-than-Expected Q1 Loss and Revenue Miss

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Nurix Therapeutics reported a loss of $0.79 per share, wider than the estimated loss of $0.76.

2The company's revenue lagged behind analyst estimates for the first fiscal quarter.

Nurix Therapeutics Inc. (NRIX) reported a net loss of $0.79 per share for the first fiscal quarter, missing the Zacks Consensus Estimate of $0.76. The company's financial performance also saw revenue lagging behind analyst expectations for the period. This result represents a widening of losses compared to the same quarter last year, when the company reported a loss of $0.67 per share. The double miss on both earnings and revenue highlights ongoing financial challenges for the biotech firm. Consequently, the widening year-over-year deficit may weigh on investor sentiment in the near term. Analysts are closely monitoring the company's cash burn and future revenue streams following these disappointing results.